Just spotted something interesting in the latest fund filings. Knoll Capital picked up 245,000 shares of SSR Mining back in February, dropping $5.37 million into the position. That's a pretty meaningful move for a firm that's usually heavy into biotech plays.

What caught my eye is the strategy here. Their top holdings are mostly clinical-stage drug developers, but they're clearly building out a hard assets sleeve. They already had a GLD position, but now they're going direct with an actual mining operator instead of just holding the ETF. SSR gives them tangible production, geographic diversification across Turkey, US, Canada, and Argentina, and real cash flow that moves with gold prices.

The timing is wild though. SSR was up 180% year-over-year when they bought in at $25.91. The company had solid momentum heading into 2026 - full-year revenue hit $1.6 billion with nearly $472 million in operating cash flow. That's real production backing the stock, not just speculation.

But here's the thing: after a run like that, you gotta think about valuation. Mining is cyclical, costs can spike, and margins compress fast. The macro backdrop for gold matters a lot here. Knoll's move makes sense as portfolio diversification and a hedge if their biotech bets stall, but the stock's already done the heavy lifting. Worth watching how it trades from here.